HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Soap Maker Warned As FDA's Cosmetics Enforcement Activity Picks Up

This article was originally published in The Rose Sheet

Executive Summary

FDA has issued three warning letters to cosmetic product marketers over the past month. The agency cites Soapwalla for violative claims on bar soaps, while Star Health & Beauty's purported cosmetics and dietary supplements are not only unapproved drugs, but also adulterated in some cases due to GMP violations.

You may also be interested in...

FDA's Online Surveillance Continues With Warning Letter To Blissoma

Blissoma Holistic Skincare and Apothecary draws an FDA warning for verboten claims on its Flawless Equalizing Anti-Blemish Oil Serum and Lavish Loving Recovery Beta-Glucan Mask, among other offerings.

FDA Puts Kibosh On Perfectly Posh For Unapproved Drug Claims

Perfectly Posh, which sells a colorful range of skin, hair and bath products online and through independent social sellers, draws an FDA warning letter for claims about acne, eczema and dandruff treatment, among others.

FDA Targets DermaTox Maker In Year’s First Published Warnings To Cosmetics Firms

Healthy Habits reacts indignantly to FDA’s warning about testimonials for DermaTox products featured on its website, which the agency says identify the items as unapproved drugs. Aegeia Skin Care also receives a warning letter for structure/function and disease-treatment claims on its facial- and body-care products.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts